Trailing-twelve-month (TTM) revenue is $68.47 Million with a year-over-year growth of +15.46%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $17,631,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $16,079,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $16,038,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $18,718,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $68,466,000 |
Current P/S: $67,959,577 market capitalization ÷ $68,466,000 TTM revenue = 0.99x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T17:06:12.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $18.72M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:12:22.800Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD |
|---|---|---|---|---|---|---|
| Accutane | N/A | N/A | $10M | $18M | $20M | $19M |
| Amzeeq | N/A | N/A | N/A |
$68.47M
$68.47 Million
+15.46%
vs. $59.30M a year ago (TTM)
+5.39%
5 Year compound annual growth rate
1 Year
+15.46%
3 Year
(5.92%)
5 Year
+5.39%
10 Year
+35.62%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $63.26M | +$5.59M | +9.69% |
| 2024 | $57.67M | ($26.84M) | (31.76%) |
| 2023 | $84.51M | +$8.77M | +11.58% |
| 2022 | $75.74M | +$6.95M | +10.11% |
| 2021 | $68.79M | +$23.19M | +50.86% |
| 2020 |
TTM Growth
+15.46%
3-Year CAGR
(5.92%)
5-Year CAGR
+5.39%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 34 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T17:12:22.800Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-05-14.
| $7M |
| $6M |
| $5M |
| Dermatology Products Sales | N/A | $45M | N/A | N/A | N/A | N/A |
|---|
| Exelderm | N/A | N/A | $5M | $3M | $2M | N/A |
|---|
| License And Service | $2M | N/A | N/A | N/A | N/A | N/A |
|---|
| Other Branded Revenue | $7M | N/A | $37,000 | N/A | N/A | N/A |
|---|
| Pharmaceutical And Biotechnology Product Development | N/A | $1M | N/A | N/A | N/A | N/A |
|---|
| Qbrexza | N/A | N/A | $17M | $27M | $25M | $25M |
|---|
| Return Reserve | $3M | N/A | N/A | N/A | N/A | N/A |
|---|
| Royalty | $100,000 | N/A | N/A | N/A | N/A | N/A |
|---|
| Targadox | $28M | N/A | $22M | $8M | $3M | N/A |
|---|
| Ximino | $4M | N/A | $8M | $5M | $287,000 | N/A |
|---|
| Zilxi | N/A | N/A | N/A | $2M | $2M | $2M |
|---|
| $45.60M |
| +$8.97M |
| +24.49% |
| 2019 | $36.63M | +$9.75M | +36.26% |
| 2018 | $26.88M | ($160.70M) | (85.67%) |
| 2017 | $187.58M | +$171.10M | +1038.25% |
| 2016 | $16.48M | +$15.62M | +1809.62% |
